Roles for miRNAs in osteogenic differentiation of bone marrow mesenchymal stem cells

Wang, Jicheng; Liu, Shizhang; Li, Jingyuan; Zhao, Song; Zhi, Yi

doi:10.1186/s13287-019-1309-7

Cited by 124 publications

(98 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Jicheng Wang et al reported the role of miRNAs in the osteogenic differentiation of BMSCs. The authors identified 17 miRNAs that were upregulated and five miRNAs were downregulated, which target various genes during osteoblast differentiation when compared to undifferentiated BMSCs [107]. These findings were consistent with the findings of Ying Chen et al [108].…”

Section: Differentiation Potentials Of Bmscs and Regulationsupporting

confidence: 83%

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

Chu

Phuong

Tien

et al. 2020

IJMS

105

View full text Add to dashboard Cite

Bone marrow mesenchymal stem/stromal cells (BMSCs), which are known as multipotent cells, are widely used in the treatment of various diseases via their self-renewable, differentiation, and immunomodulatory properties. In-vitro and in-vivo studies have supported the understanding mechanisms, safety, and efficacy of BMSCs therapy in clinical applications. The number of clinical trials in phase I/II is accelerating; however, they are limited in the size of subjects, regulations, and standards for the preparation and transportation and administration of BMSCs, leading to inconsistency in the input and outcome of the therapy. Based on the International Society for Cellular Therapy guidelines, the characterization, isolation, cultivation, differentiation, and applications can be optimized and standardized, which are compliant with good manufacturing practice requirements to produce clinical-grade preparation of BMSCs. This review highlights and updates on the progress of production, as well as provides further challenges in the studies of BMSCs, for the approval of BMSCs widely in clinical application.

show abstract

Section: Differentiation Potentials Of Bmscs and Regulationsupporting

confidence: 83%

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

Chu

Phuong

Tien

et al. 2020

IJMS

105

View full text Add to dashboard Cite

show abstract

“…Multiple miRNAs regulate the osteogenic differentiation of BMMSCs [40]. For example, microRNA-218-5p targets COL1A1 to promote osteogenic differentiation of OVX-BMMSCs in vitro [41]; while microRNA-145 suppresses the osteogenic differentiation of human BMMSCs [42].…”

Section: Shed-evs Into Bmmscs Of Recipient Ovx Micementioning

confidence: 99%

Extracellular vesicles from deciduous pulp stem cells recover bone loss by regulating telomerase activity in an osteoporosis mouse model

Sonoda

Murata

Nishida

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Systemic transplantation of stem cells from human exfoliated deciduous teeth (SHED) induces bone regeneration in animal models of osteoporosis; however, the mechanisms underlying this remain unclear. Here, we hypothesized that trophic factors within SHED-releasing extracellular vesicles (SHED-EVs) rescue osteoporotic phenotype.Methods: EVs were isolated from culture supernatant of SHED. SHED-EVs were treated with or without ribonuclease and systemically administrated into ovariectomized mice, followed by the measurement of bone regenerative function of recipient bone marrow mesenchymal stem cells (BMMSCs) including Tert expression. Subsequently, human BMMSCs were stimulated by SHED-EVs with or without ribonuclease treatment, and then human BMMSCs were examined osteogenic function in vitro and telomerase activity. Furthermore, SHED-EVs treated human BMMSCs were subcutaneously transplanted into dorsal skin of immunocompromised mice with hydroxyapatite tricalcium phosphate (HA/TCP) careers and analyzed the de novo bone forming ability.Results: We revealed that systemic SHED-EV-infusion recovered bone volume in ovariectomized mice and improved osteogenic function of recipient BMMSCs by rescuing the mRNA levels of Tert and telomerase activity. Ribonuclease treatment depleted RNAs, including microRNAs, within SHED-EVs and these RNA-depleted SHED-EVs attenuated SHED-EV-triggered bone regeneration and telomerase-mediated osteogenesis in the ovariectomized mice. These findings were supported by in vitro osteogenic assays using human BMMSCs incubated with SHED-EVs.Conclusion: Collectively, our findings suggest that SHED-secreted trophic factors, specifically microRNAs, play a crucial role in treating postmenopausal osteoporosis by targeting the telomerase activity of recipient BMMSCs.

show abstract

“…It has been extensively reported that MM cells are able to induce the remodeling of the bone marrow stromal tissue to promote their growth and survival. For this purpose, the bidirectional crosstalk between MM cells and Bone marrow stromal cells (BMSCs) is crucial [6].BMSC differentiation is regulated by a number of cytokines as well as miRNAs [7,8]. To note, several miRNAs can exhibit inhibitory roles in osteogenesis by directly or indirectly targeting key osteogenic factors [9].…”

Section: Introductionmentioning

confidence: 99%

Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma

Raimondo

Urzì

Conigliaro

et al. 2020

Cancers

View full text Add to dashboard Cite

Osteolytic bone disease is the major complication associated with the progression of multiple myeloma (MM). Recently, extracellular vesicles (EVs) have emerged as mediators of MM-associated bone disease by inhibiting the osteogenic differentiation of human mesenchymal stem cells (hMSCs). Here, we investigated a correlation between the EV-mediated osteogenic inhibition and MM vesicle content, focusing on miRNAs. By the use of a MicroRNA Card, we identified a pool of miRNAs, highly expressed in EVs, from MM cell line (MM1.S EVs), expression of which was confirmed in EVs from bone marrow (BM) plasma of patients affected by smoldering myeloma (SMM) and MM. Notably,we found that miR-129-5p, which targets different osteoblast (OBs) differentiation markers, is enriched in MM-EVs compared to SMM-EVs, thus suggesting a selective packaging correlated with pathological grade. We found that miR-129-5p can be transported to hMSCs by MM-EVs and, by the use of miRNA mimics, we investigated its role in recipient cells. Our data demonstrated that the increase of miR-129-5p levels in hMSCs under osteoblastic differentiation stimuli inhibited the expression of the transcription factor Sp1, previously described as a positive modulator of osteoblastic differentiation, and of its target the Alkaline phosphatase (ALPL), thus identifying miR-129-5p among the players of vesicle-mediated bone disease.

show abstract

Roles for miRNAs in osteogenic differentiation of bone marrow mesenchymal stem cells

Cited by 124 publications

References 73 publications

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

Extracellular vesicles from deciduous pulp stem cells recover bone loss by regulating telomerase activity in an osteoporosis mouse model

Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma

Contact Info

Product

Resources

About